Meeting Banner
Abstract #3864

Predicting Response to Sunitinib Second-line Therapy in Gastrointestinal Stromal Tumors Using Non-Gaussian Diffusion MRI

Yi Sui 1,2 , Lei Tang 3 , Kejia Cai 2,4 , Shun-Yu Gao 3 , Frederick C. Damen 2,4 , Ying-Shi Sun 3 , and Xiaohong Joe Zhou 2,5

1 Bioengineering, University of Illinois at Chicago, Chicago, IL, United States, 2 Center for MR Research, University of Illinois Hospital & Health Sciences System, Chicago, IL, United States, 3 Radiology, Peking University Cancer Hospital & Institute, Beijing, China, 4 Radiology, University of Illinois Hospital & Health Sciences System, Chicago, IL, United States, 5 Departments of Radiology, Neurosurgery and Bioengineering, University of Illinois Hospital & Health Sciences System, Chicago, IL, United States

Sunitinib offers a second line treatment to gastrointestinal stromal tumor (GIST) patients with imatinib-resistant progressive lesions. Prediction of the treatment response is crucial for achieving optimal outcomes. We used a non-Gaussian diffusion model, known as the fractional order calculus model (FROC), to assess the early response to sunitinib treatment in imatinib-resistant GIST lesions. Our results showed that the FROC model outperformed the conventional means of using tumor size in predicting tumor response at as early as 2 weeks after receiving sunitinib treatment. This study suggests that non-Gaussian diffusion imaging can provide timely information to evaluate sunitinib targeted therapy of GIST.

This abstract and the presentation materials are available to members only; a login is required.

Join Here